MXPA05008902A - Soluciones de drogas en mentol. - Google Patents

Soluciones de drogas en mentol.

Info

Publication number
MXPA05008902A
MXPA05008902A MXPA05008902A MXPA05008902A MXPA05008902A MX PA05008902 A MXPA05008902 A MX PA05008902A MX PA05008902 A MXPA05008902 A MX PA05008902A MX PA05008902 A MXPA05008902 A MX PA05008902A MX PA05008902 A MXPA05008902 A MX PA05008902A
Authority
MX
Mexico
Prior art keywords
drugs
menthol solutions
menthol
solutions
compositions
Prior art date
Application number
MXPA05008902A
Other languages
English (en)
Spanish (es)
Inventor
Moldavski Naomi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA05008902A publication Critical patent/MXPA05008902A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05008902A 2003-02-20 2004-02-17 Soluciones de drogas en mentol. MXPA05008902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44924603P 2003-02-20 2003-02-20
PCT/US2004/004684 WO2004073686A2 (en) 2003-02-20 2004-02-17 Menthol solutions of drugs

Publications (1)

Publication Number Publication Date
MXPA05008902A true MXPA05008902A (es) 2005-10-05

Family

ID=32908699

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008902A MXPA05008902A (es) 2003-02-20 2004-02-17 Soluciones de drogas en mentol.

Country Status (10)

Country Link
US (1) US20040198646A1 (enExample)
EP (1) EP1596832A2 (enExample)
JP (1) JP2006524190A (enExample)
KR (1) KR20050116368A (enExample)
CN (1) CN1882313A (enExample)
AU (1) AU2004212989A1 (enExample)
CA (1) CA2516798A1 (enExample)
EA (1) EA200501301A1 (enExample)
MX (1) MXPA05008902A (enExample)
WO (1) WO2004073686A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034920A1 (en) 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
WO2005094814A1 (ja) * 2004-03-31 2005-10-13 Kowa Co., Ltd. 外用剤
EP1720523A2 (en) * 2004-08-13 2006-11-15 Teva Pharmaceutical Industries Ltd Cyclosporin formulations
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20060222707A1 (en) * 2005-03-30 2006-10-05 Lerner E I Formulations of fenofibrate
MX2007011858A (es) * 2005-03-30 2008-03-25 Teva Pharma Formulaciones mejoradas de fenofibrato que contienen mentol o peg/poloxamero.
AU2006264407B2 (en) * 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
JP2022548221A (ja) * 2019-09-09 2022-11-17 テジュン ファーマシューティカル カンパニー リミテッド シクロスポリンおよびメントール含有ナノエマルジョン点眼組成物およびその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
AU2190697A (en) * 1996-04-12 1997-11-07 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
US20010049363A1 (en) * 1998-05-08 2001-12-06 Warner-Lambert Company Oral composition containing NSAIDs and essential oils
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
DE60330322D1 (de) * 2002-03-26 2010-01-14 Teva Pharma Arzneimittel-mikroteilchen

Also Published As

Publication number Publication date
WO2004073686A2 (en) 2004-09-02
EP1596832A2 (en) 2005-11-23
US20040198646A1 (en) 2004-10-07
AU2004212989A1 (en) 2004-09-02
WO2004073686A3 (en) 2004-11-04
JP2006524190A (ja) 2006-10-26
KR20050116368A (ko) 2005-12-12
CA2516798A1 (en) 2004-09-02
CN1882313A (zh) 2006-12-20
EA200501301A1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
TW200716646A (en) (S)-N-methylnaltrexone
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
TW200510416A (en) P38 inhibitors and methods of use thereof
TW200637522A (en) Skin treatment articles and methods
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
CA2672094C (en) Methods and apparatus for identifying subject matter in view data
MY146112A (en) Long-term feed - cancer patient
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
IL169897A0 (en) Sustituted heterocycles
MX2010005589A (es) Composicion para el cuidado personal.
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
MXPA05008902A (es) Soluciones de drogas en mentol.
IL186707A (en) Mitotic quinine inhibitors and medical preparations containing them
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
NO20076120L (no) Stabile nanopartikkelformuleringer
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
SE0300457D0 (sv) Novel compounds
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
WO2006020984A3 (en) Cyclosporin formulations
MX2007000399A (es) Forma de dosis estable para derivados de fenilalanina.